| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.32 | 2e-12 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-07 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-06 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-06 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.16 | 7e-06 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |